HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, Zhan P, Xu Y, Lv J, Qian J, Liu C, Sun Y, Qian Z, Zhang J, Gu Y, Ni X.
Liu YJ, et al. Among authors: qian j, qian z.
Br J Cancer. 2014 Mar 4;110(5):1169-78. doi: 10.1038/bjc.2014.61. Epub 2014 Feb 11.
Br J Cancer. 2014.
PMID: 24518603
Free PMC article.